250 studies found for:    Open Studies | "Hodgkin Disease"
Show Display Options
Rank Status Study
21 Recruiting A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity
Condition: Hodgkin Disease
Intervention: Drug: Brentuximab Vedotin
22 Recruiting Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Intervention: Drug: Temsirolimus
23 Recruiting Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Adriamycin;   Drug: Dacarbazine
24 Recruiting Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
Conditions: Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Other: laboratory biomarker analysis;   Genetic: protein expression analysis
25 Recruiting Ipilimumab, Nivolumab, and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Adult Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
26 Recruiting Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Adult Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis
27 Unknown  Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)
Condition: Hodgkin's Lymphoma
Intervention: Drug: Oxaliplatin-based chemotherapy (ESHAOx)
28 Recruiting Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Reduced Intensity Conditioning
29 Recruiting Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
Condition: Hodgkins Lymphoma
Intervention: Biological: allogeneic donor derived LMP specific cytotoxic T-lymphocyte
30 Not yet recruiting Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   Non-Hodgkin's Lymphoma;   Non-Hodgkin Lymphoma;   Hodgkin Disease;   Hodgkins Disease;   Hodgkin's Disease;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm
Interventions: Drug: BL-8040;   Procedure: Leukapheresis;   Procedure: Hematopoietic cell transplant
31 Recruiting HD17 for Intermediate Stage Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone);   Drug: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine);   Radiation: 30Gy IF-RT (Involved-Field Radiotherapy);   Radiation: 30Gy IN-RT (Involved-Node Radiotherapy)
32 Recruiting Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: dose dense ABVD
33 Unknown  IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: IGEV
34 Recruiting Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL
Conditions: Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma
Intervention: Drug: Pembrolizumab
35 Recruiting GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: AFM13
36 Recruiting Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: Stanford V Chemotherapy;   Radiation: Radiation Therapy
37 Unknown  Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Interventions: Drug: R-mabHDI and ABVD;   Drug: ABVD
38 Not yet recruiting Brentuximab for Newly Diagnosed Hodgkin Disease
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Rituximab
39 Not yet recruiting Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
Condition: Hodgkins Lymphoma
Intervention: Biological: Avelumab
40 Recruiting A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.
Condition: Hodgkin Lymphoma
Intervention: Drug: Brentuximab Vedotin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years